Clinical and genetic factors associated with the risk of recurrent ischemic events in patients with stable stenocardia

The aim of the study was to assess the clinical and genetic factors associated with the risk of recurrent ischemic events in patients with stable stenocardia (SS). Materials and methods. A total of 100 patients with SS were examined and followed-up for 15.3±8.3 months. The patients were divided into subgroups (SG): SG1 (n=51) – persons without events, SG2 (n=49) persons with recurrent ischemic events (hospitalization due to the development of pain syndrome, re-stenting due to stent restenosis, myocardial infarction, cerebral infarction and death from cardiovascular causes), SGB (n=11) – persons with «major» recurrent ischemic events (re-stenting due to stent restenosis, myocardial infarction, cerebral infarction and death from cardiovascular causes) , SGG (n=89) – persons without «major» events. The obtained survey data (general clinical, aggregometry, polymor  phism of genes of platelet fibrinogen receptor ITGB3 (T1565C), platelet collagen receptor ITGA2 (C807T), ADP platelet receptor P2RY12, H1/H2 (T744C)) were analyzed using the STATISTICA 10.0 software. Results. In SG2, men predominated (χ² =9.2; p<0.01), past MI was more common (χ² =4.8; p<0.05), more stents were implanted (2.4±1.9 versus 1.7±1.1, p<0.05), TRAP-test values were higher (p<0.05) compared to SG1. In SGB, greater number of stents were implanted (3.1±2.2 versus 1.61±1.57, p<0.05), the carriage of the TC genotype of the ITGB3 gene was more common, (p<0.05), a combination of gene mutations ITGB3 and P2RY12 was more common, (p<0.05) compared to SGG. A logistic regression equation was constructed, including the presence of diabetes mellitus, the number of platelets in the blood test, the ASPI-test values, the carriage of the 1565C allele of the ITGB3 gene, the number of stents implanted, which makes it possible to determine the likelihood of developing «major» recurrent ischemic events with a cut-off threshold LP₀=0.0965, with sensitivity – 81.82 %, specificity – 78.48 %, overall accuracy – 78.89 %. Conclusions. The factors associated with the development of recurrent ischemic events are: male sex, previous MI, a greater number of implanted stents, and high TRAP-test values. The factors associated with the development of recurrent «major» ischemic events are: a greater number of implanted stents, carriage of the TC genotype of the ITGB3 gene, carriage of a combination of mutations of the H1/H2 polymorphic locus of the P2RY12 gene and the T1565C polymorphic locus of the ITGB3 gene, diabetes mellitus, the number of platelets in blood test, ASPI-test values.

1. Mitkovskaya NP, Laskina OV, Teefy Patrick Unstable angina pectoris or unstable coronary syndromes? Emergency cardiology and cardiovascular risks. 2020;4(1):816–849. (In Russ.) Doi: 10.51922/2616-633x.2020.4.2.944.

2. Lindemann S, Kramer B, Daub K, Stellos K, Gawaz M. Molecular pathways used by platelets to initiate and accelerate atherogenesis. Current Opinion in Lipidology. 2007; 18(5):566–573. Doi: 10.1097/MOL.0b013e3282ef7c1e.

3. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and metaanalysis. Archives of Internal Medicine. 2007;167(15):1593–1599. Doi: 10.1001/archinte.167.15.1593.

4. Warlo EMK, Arnesen H, Seljeflot I. A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease. Thrombosis Journal. 2019;17(1):2–9. Doi: 10.1186/s12959-019-0197-5.

5. Amin AM, Sheau Chin L, Azri Mohamed Noor D, Sk Abdul Kader MA, Kah Hay Y, Ibrahim B. The personalization of clopidogrel antiplatelet therapy: the role of integrative pharmacogenetics and pharmacometabolomics. Cardiol Res Pract. 2017;(2017):8062796. Doi: 10.1155/2017/8062796.

6. Wurtz M. Aspirin in Coronary Artery Disease. An Appraisal of Functions and Limitations // Danish Medical Journal. 2015;62(4):B5011.

7. Geisler T, Schaeffeler E, Gawaz M, Schwab M. Genetic variation of platelet function and pharmacology: An update of current knowledge // Thrombosis and Haemostasis. 2013;(110):876–887. Doi: 10.1160/TH13-02-0145.

8. Calatzis A, Loreth R, Spannagl M. Multiplate platelet function analysis – application and interpretation. Verum Diagnostica // GmbH. 2007:35.

9. Kopytskiy AV, Khilmanovich VN. Software for constructing sets of regression models on samples of limited size in medical research // Sakharov Readings of 2019: Environmental Problems of the 21st Century:Proceedings of the 19th International Scientific Conference. ITC of the Ministry of Finance. Minsk, Republic of Belarus, 2019;(3):205–208. (In Russ.)

10. Kovsh EV, Leshkevich KF, Dinsevich TL. The factors and the varients of course the ischemic heart disease. Health and Ecology Issues. 2007;(3):27–32. (In Russ.)

11. Komarov AL., Moskovkina ES. Modern approaches to risk stratification of patients undergoing elective percutaneous coronary interventions. Atherothrombosis. 2016;(2):65–80. (In Russ.) Doi: 10.21518/2307-1109-2016-2-65-80.

12. Shalnova SA, Deev AD, Kapustina AV, Evstifeeva SE, Muromtseva GA, Tuaeva EM, Balanova YuA, Konstantinov VV, Kiseleva NV, Shkolnikova MA. Coronary heart disease in persons older than 55 years. prevalence and prognosis. Cardiovascular Therapy and Prevention. 2014;13(4):21–28. (In Russ.) Doi: 10.15829/1728-8800-2014-4-21-28.

13. Stelmashok VI, Polonetsky OL, Koush EV, Pashkevich SF, Kavalenka DV. Six months results after coronary artery chronic total occlusion recanalization by antegrade approach. Emergency cardiology and cardiovascular risks. 2018;2(1):208–215. (In Russ.)

14. Golukhova EZ, Grigoryan MV, Ryabinina MN, Bulaeva NI. Clinical and laboratory predictors of major adverse cardiac events in patients with ischemic heart disease following elective percutaneous coronary intervention. Rational Pharmacotherapy in Cardiology. 2016;12(5):528– 535. (In Russ.) Doi: 10.20996/1819-6446-2016-12-5-528-535.

15. Shumakov DV, Shekhyan GG, Zybin DI, Yalymov AA, Stepina EV, Popov MA. Late complications of percutaneous coronary interventions. RMJ. 2020;(10):25–28. (In Russ.)

16. Novikova ES, Komarov AL, Gus’kova EV, Shakhmatova OO, Deyev AD, Dobrovolsky AB, Samko AN, Panchenko EP. Is the syntax score sufficient to assess the risk for patients undergoing elective percutaneous coronary interventions? Atherothrombosis. 2017;(1):80–93. (In Russ.) Doi: 10.21518/2307-1109-2017-1-80-93.

17. Strisciuglio T, Franco D, Di Gioia G, De Biase C, Morisco C, Trimarco B, Barbato E. Impact of genetic polymorphisms on platelet function and response to anti platelet drugs // Cardiovasc Diagn Ther. 2018;8(5):610–620. Doi: 10.21037/cdt.2018.05.06.

18. Andrenko EYu, Samokhodskaya LM, Balatskiy AV, Makarevich PI, Boytsov SA. Prognostic significance of the carriage of allelic variants of genes controlling the hemostasis system and their combination with traditional risk factors in early development coronary heart disease // Cardiovascular therapy and prevention. 2011;10(8):32–39. (In Russ.)

19. Kurupanova AS, Lareva NV. Association of ITGB3 and ITGA2 polymorphisms with clinical course and outcomes in acute coronary syndrome with ST segment elevation. Transbaikal Medical Bulletin. 2019;(2):27–39. (In Russ.)

20. Pina-Cabral LB, Carvalhais V, Mesquita B, Escуrcio C, Silva PF, Pinto P, Napoleгo P, Pinheiro T, Monteiroa MC, Almeida-Dias A, Criado B. Myocardial infarction before and after the age of 45: Possible role of platelet receptor polymorphisms. Revista Portuguesa de Cardiologia. 2018;(37):727– 735. Doi: 10.1016/j.repc.2018.03.015.

21. Liu H, Wang Y, Zheng J, Li G, Chen T, Lei J, Mao Y, Wang J, Liu W, Zhao G, Tacey M, Yan B. Platelet glycoprotein gene Ia C807T, HPA-3, and Ibα VNTR polymorphisms are associated with increased ischemic stroke risk: Evidence from a comprehensive meta-analysis // International Journal of Stroke. 2017;12(1):46–70. Doi: 10.1177/1747493016672085.

22. Leone А, Stefano V, Burzotta F, Chiusolo P, Casorelli I, Paciaroni K, Rossi E, Sciahbasi A, Testa L, Leone G, Crea F, Andreotti F. Glycoprotein Ia C807T gene polymorphism and increased risk of recurrent acute coronary syndromes: a five year follow up // Heart. 2004;(90):567–569. Doi: 10.1136/hrt.2003.017624.

23. Ye Zh, Liu E, Higgins J, Keavney B, Lowe G, Collins R, Danesh J. Seven haemostatic gene polymorphismsin coronary disease: meta-analysis of 66,155 cases and 91,307 controls // Lancet. 2006;367(9511):651–658. Doi: 10.1016/S0140-6736(06)68263-9.

24. Hoppmann P, Koch W, Laugwitz KL, Kastrati A. Genetic risk of restenosis after percutaneous coronary interventions in the era of drug-eluting stents // Coronary Artery Disease. 2014;25(8):658–664. Doi: 10.1097/MCA.0000000000000149.

25. Grinshtein YI, Kosinova AA, Grinshtein IY, Subbotina TN, Savchenko AA. The prognostic value of combinations of genetic polymorphisms in the ITGB3, ITGA2, and CYP2C19*2 genes in predicting cardiovascular outcomes after coronary bypass grafting // Genetic testing and molecular biomarkers. 2018;22(4):1–7. Doi: 10.1089/gtmb.2017.0177.

26. Karazhanova LK, Zhukusheva ShT, Chinybaeva AA. Molecular genetic basis for the diagnosis and treatment of coronary heart disease // Science and health care. 2014;(3):4–11. (In Russ.)].

27. Xiang Q, Ji Sh, Zhang Zh, Zhao X, Cui YM. Identification of ITGA2B and ITGB3 single-nucleotide polymorphisms and their influences on the platelet function // BioMed Research International. 2016;(1):1–11. Doi: 10.1155/2016/5675084.

28. Jastrzebska M, Lisman D, Szelepajlo A, Oledzki S, Chelstowski K, Clark JS, Siennicka A. Evaluation of platelet reactivity during combined antiplatelet therapy in patients with stable coronary artery disease in relation to diabetes type 2 and the GPIIB/IIIA receptor gene polymorphism // Journal Of Physiology And Pharmacology. 2019;70(2):175–185. Doi: 10.26402/jpp.2019.2.01.

29. Cayla G, Hulot JS, O’Connor SA, Pathak A, Scott SA, Gruel Y, Silvain J, Vignalou JB, Huerre Y, de la Briolle A, Allanic F, Beygui F, Barthйlйmy O, Montalescot G, Collet JP. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis // JAMA. 2011;306(16):1765– 1774. Doi: 10.1001/jama.2011.1529.

30. Zee RY, Michaud ShE, Diehl KA, Chasman DI, Emmerich J, Gaussem P, Aiach M, Ridker PM. Purinergic receptor P2Y, G protein coupled, 12 gene variants and risk of incident ischemic stroke, myocardial infarction, and venous thromboembolism // Atherosclerosis. 2008;197(2):694–699. Doi: 10.1016/j.atherosclerosis.2007.07.001.

31. Fontana P, Dupont A, Gandrille S, Bachelot-Loza Ch, Reny JL, Aiach M. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects // Circulation. 2003;(108):989–995. Doi: 10.1161/01.CIR.0000085073.69189.88.

32. Li M, Wang H, Xuan L, Shi X, Zhou T, Zhang N, Huang Y. Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome // Medicine (Baltimore). 2017;96(14):6553. Doi: 10.1097/MD.0000000000006553.